Danaher Co. (NYSE:DHR) Stock Position Lowered by Regency Capital Management Inc. DE

Regency Capital Management Inc. DE lessened its position in Danaher Co. (NYSE:DHR) by 4.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 21,751 shares of the conglomerate’s stock after selling 1,035 shares during the quarter. Danaher makes up about 3.3% of Regency Capital Management Inc. DE’s holdings, making the stock its 12th biggest holding. Regency Capital Management Inc. DE’s holdings in Danaher were worth $6,047,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in DHR. Tsfg LLC lifted its position in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the 2nd quarter valued at approximately $25,000. nVerses Capital LLC acquired a new position in shares of Danaher during the 2nd quarter worth $25,000. Redmont Wealth Advisors LLC acquired a new position in shares of Danaher during the 1st quarter worth $30,000. Finally, Richardson Financial Services Inc. acquired a new position in shares of Danaher during the 4th quarter worth $42,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of NYSE:DHR traded down $0.49 during midday trading on Friday, reaching $270.03. 1,132,662 shares of the company’s stock were exchanged, compared to its average volume of 2,759,666. The company’s 50 day simple moving average is $271.15 and its two-hundred day simple moving average is $258.43. The firm has a market capitalization of $200.01 billion, a PE ratio of 45.78, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same period last year, the firm earned $2.05 EPS. Equities research analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Leerink Partners increased their price target on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Barclays increased their price target on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group raised their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Stephens initiated coverage on shares of Danaher in a research note on Tuesday. They issued an “overweight” rating and a $315.00 target price on the stock. Finally, StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $282.12.

Insider Buying and Selling

In related news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 in the last quarter. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.